Mumbai, Naples, November 4, 2026: Global pharmaceutical company Lupin Limited (Lupin) today announced the appointment of Akhil Gupta as an Independent Director to its Board.
Akhil Gupta brings more than four decades of experience in building and scaling businesses, corporate strategy, finance, governance, and mergers and acquisitions. As Vice Chairman of Bharti Enterprises Limited, he played a pivotal role in the group’s growth from inception, both organically and through acquisitions. A qualified Chartered Accountant, he has also completed the Advanced Management Program at Harvard Business School.
He currently serves as Non-Executive Independent Chairman of 360 ONE WAM, Coforge and Valuedrive Technologies Ltd (Spinny); Independent Director of Lodha Developers and Zepto; and Nominee Director of Acevector Limited. He is also President of the Telecom Sector Skill Council, a Member of the CII National Committee on Telecom & Broadband and the CII Task Force on Insolvency and Bankruptcy, and Chairman of Inversion Advisory Services. In addition, he advises leading companies across infrastructure, renewable energy, automobiles, tourism, consulate services and footwear.
His recognitions include the EY Entrepreneur of the Year Award (Entrepreneur CEO), CA Global Achiever, CA Business Achiever, CEO of the Year Award, and CNBC TV18 Best CFO Awards.
Manju D Gupta, Chairperson, Lupin, said, “We are delighted to welcome Akhil to the Lupin Board. He brings a rare combination of strategic perspective, financial acumen, governance experience, and a proven track record of building businesses at scale. His counsel will be valuable as Lupin continues to strengthen its global position and pursue its next phase of growth.”
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company’s business strategy.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com
